SUSAN ADAMS: Open Payments
NPI 1922004332 · MACOMB, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$867 in 42 payments from 16 companies in 2025. Trend: 2023 $858 · 2024 $1,183 · 2025 $867
Food & beverage: $867
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $154 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Abbott Laboratories | 3 | $58 |
| Almatica Pharma LLC | 2 | $49 |
| ABBVIE INC. | 3 | $42 |
| Lilly USA, LLC | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
Products named: CAPLYTA, JARDIANCE, BREZTRI, REXULTI, FREESTYLE LIBRE 3, FARXIGA, LOREEV XR, VRAYLAR.
Industry payments across IL — which companies pay providers there.
